Medi-Qualité Omega

We provide tailored strategic consulting services for pharma and biotech companies, with a Global and European focus.

Mission statement & Expertise

Our Comparative Advantage lies in our in-house transversal expertise from a pharma, clinical, public health, basic science, and a payer perspective, with diverse geographic origins.

The team is supported by our network of international HTA experts and decision-makers.

We work throughout the development phase of a product up to the negotiation with payers, with a special focus on disruptive innovations.

Illustration - Team alternative
Team alternative

Our core competence

02.
Parallel/early Scientific Advice 
Official HAS/EMA/EUnetHTA
Mock Parallel/early Scientific Advice

04.
Strategic / flash assessment on EU / global submission

06.
EU Launch Sequence Strategy

01.
Investment Assessment on POC

03.
3A. Flash Advice for due diligence on a TPP

3B. Best prepare for 2025 EU Clinical effectiveness assessment

05.
HTA Advisory Board

07.
P&R Negotiation Capability-Building Workshop
US/EU/France
Emerging Markets 

Early assessment


Phase 1

01.
Investment Assessment on POC

Phase 2

02.
Parallel/early Scientific Advice 
Official HAS/EMA/EUnetHTA
Mock Parallel/early Scientific Advice

03.
3A. Flash Advice for due diligence on a TPP

3B. Best prepare for 2025 EU Clinical effectiveness assessment

Pre-Submission advice


Phase 3

04.
Strategic / flash assessment on EU / global submission

05.
HTA Advisory Board

Pre-launch


06.
EU Launch Sequence Strategy

Launch


07.
P&R Negotiation Capability-Building Workshop
US/EU/France
Emerging Markets 

Leadership team

Carinne Simoes
M.B.A
CEO / Partner
Hanim Edoo
M.Sc
Head Market Access
Olivier Wong
MD
CMO / Partner
Sandrine Valenciennes
M.Sc
Office Manager

OUR GLOBAL EXPERT NETWORK

36
Countries covered 


220
Payer & HTA experts

Illustration - Map
Map

Contact us


MQO

27 rue Blomet
75015 Paris
France
+33 (0)9 66 97 82 58